Superworth

Zevra Therapeutics EPS ZVRA

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
$0.93
Latest quarter, Q2 FY26
$0.14
−88% on a year earlier
Fiscal year 2025
$1.34

Zevra Therapeutics' earnings per share was $0.93 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was $0.14, down 88% on the same quarter a year before.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025$1.34n/a
FY2024n/an/a
FY2021−$3.03n/a
FY2020−$3.46n/a
FY2019−$14.56n/a
FY2018−$61.12n/a
FY2017−$47.20n/a
FY2016−$18.72n/a
FY2015−$100.32n/a
FY2014−$164.32n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26$0.14−88%$0.93
Q1 FY26$0.60n/a$2.00
Q4 FY25$0.20n/a$1.34
Q3 FY25−$0.01n/a$0.47
Q2 FY25$1.21n/a−$0.21
Q1 FY25−$0.06n/a−$1.90
Q4 FY24−$0.67n/an/a
Q3 FY24−$0.69n/an/a
Q2 FY24−$0.48n/an/a
Q4 FY21−$0.08n/a−$3.03
Q3 FY21−$0.06n/a−$4.02
Q2 FY21−$0.40−290%−$4.64

Against its peers

Companies in Drug Manufacturers - General nearest Zevra Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ZVRAZevra Therapeutics$0.93
IRWDIronwood Pharmaceuticals$0.77
PBYIPuma Biotechnology$0.52−47% a year
CRMDCorMedix$2.13+184% a year
ARVNArvinas$0.16
COLLCollegium Pharmaceutical$1.24+19% a year
ABUSArbutus Biopharma$0.78
AMPHAmphastar Pharmaceuticals$1.70−36% a year
OMEROmeros$1.52
PCRXPacira BioSciences$0.35
ANABAnaptysbio$4.57
Peer median$1.01

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Zevra Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.